摘要
目的探讨曲美他嗪在尿毒症性心肌病临床中的应用价值。方法整群选取在该院接诊的56例尿毒症性心肌病患者作为观察组,并采用曲美他嗪进行治疗。将同期在该院接受治疗的55例尿毒症性心肌病患者的临床资料作为对照组,并采用常规治疗的方法。两组尿毒症性心肌病患者接受不同的临床治疗,对比临床疗效及心功能改善情况。结果在接受不同治疗情况下,对照组临床治疗总有效率为74.54%,观察组临床治疗总有效率为91.07%,对两组患者的临床治疗效果进行比较,差异具有统计学意义(P<0.05);两组患者不良反应对比,差异有统计学意义(P<0.05)。结论在尿毒症性心肌病的临床治疗过程中,曲美他嗪能够改善患者的心肌功能,有效改善患者的心肌重构,疗效显著,值得临床推广和应用。
Objective To analyze the clinical effect of trimetazidine in the treatment of uremic cardiomyopathy. Methods 56 patients suffering from uremic cardiomyopathy who were admitted into this hospital and treated with trimetazidine were assigned to the observation group, while other 55 patients with uremic cardiomyopathy underwent conventional treatment in this hospital in the same period were assigned to the control group. The efficacy and improvement of patients' cardiac function were compared between the methods performed in the two groups. Results The overall effective rate was 74.54% in the control group and 91.07% in the observation group, and the difference was statistically significant between them who were treated differently, P<0.05; in terms of adverse reaction, a statistically significant difference can be observed between the two groups, too, P<0.05. Conclusion In the treatment of patients with uremic cardiomyopathy, trimetazidine can improve patients' cardiac function and myocardial remodeling with remarkable effect, therefore it is worthy of promotion and application.
出处
《中外医疗》
2015年第30期110-111,共2页
China & Foreign Medical Treatment
关键词
尿毒症性心肌病
曲美他嗪
疗效
观察
Uremic cardiomyopathy
Trimetazidine
Efficacy
Observation
